Experts discuss treating hematologic malignancies during the COVID-19 pandemic, reducing nosocomial COVID-19 infections, clinical trial participation, and resource allocation. They highlight challenges in patient management, resource distribution, and the use of telemedicine. The impact on clinical trials, treatment considerations, and the need for international collaboration are also discussed.